Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.11.18	Ausblick: Nektar Therapeutics präsentiert Quartalsergebnisse (finanzen.net)
24.09.18	BioXcel Expands Collaboration With Nektar To Initiate New Clinical Program (RTTNews)
09.08.18	FDA Panel Nod For PRTK, INSY Settles With DOJ, Rite Aid Scraps Merger Deal (RTTNews)
08.08.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
31.07.18	LXRX On Watch, NKTR To Face FDA In May, TNDM Boosts Sales Outlook (RTTNews)
14.06.18	New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th... (PR Newswire)
05.06.18	Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York (PR Newswire)
03.06.18	Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 (PR Newswire)
31.05.18	Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to... (PR Newswire)
31.05.18	CRSP Falls On Clinical Hold, PFE Gets FDA Nod, ARWR To Report Data In Nov. (RTTNews)
30.05.18	Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration (PR Newswire)
17.05.18	FDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On Watch (RTTNews)
17.05.18	Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
10.05.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
10.05.18	Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 (PR Newswire)
08.05.18	Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus (PR Newswire)
03.05.18	Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets (PR Newswire)
30.04.18	Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting (PR Newswire)
24.04.18	Nektar Enters Into New Clinical Collaboration With Takeda (RTTNews)
24.04.18	New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors (PR Newswire)
16.04.18	MÄRKTE USA/Freundlich - Vorschusslorbeeren für Quartalszahlen (Dow Jones)
16.04.18	Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 (PR Newswire)
11.04.18	Nektar Therapeutics Begins Dosing Patients In Phase 1/2 REVEAL Clinical Study (RTTNews)
11.04.18	Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors (PR Newswire)
03.04.18	Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb (PR Newswire)
12.03.18	Nektar Therapeutics Turns Negative After Reaching Record High (RTTNews)
09.03.18	Take-Two Interactive Software, SVB Financial and Nektar Pharmaceuticals Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
07.03.18	Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston (PR Newswire)
01.03.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
01.03.18	Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results (PR Newswire)
22.02.18	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets (PR Newswire)
15.02.18	AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz (RTTNews)
10.01.18	PTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBT (RTTNews)
02.01.18	Hyland Healthcare Partners with Jopari to Offer OnBase Mackinac Access (PR Newswire)
27.11.17	Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City (PR Newswire)
24.11.17	Nektar Therapeutics Turns Higher After Seeing Initial Weakness (RTTNews)
24.11.17	Bayer erleidet Rückschlag bei Studie zu Amikacin (Dow Jones) Die Bayer AG mit einem Kombinationsprodukt zur Behandlung von Lungenentzündung einen Rückschlag erlitten.» mehr
24.11.17	Bayer Says INHALE Did Not Demonstrate Superiority (RTTNews)
24.11.17	Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority (PR Newswire)
22.11.17	Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline (PR Newswire)
17.11.17	Are You Keeping An Eye On EARS And 6 Other Pharma Stocks? (RTTNews)
16.11.17	SGMO Emerges Champion, Mark Your Calendar For ANTH, No Stopping NKTR (RTTNews)
14.11.17	NKTR's Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave Rises (RTTNews)
13.11.17	FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
11.11.17	First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative... (PR Newswire)
10.11.17	Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference (PR Newswire)
08.11.17	XOMA Shines, PTGX Awaits Data, SELB Implodes, No Stopping NKTR (RTTNews)
07.11.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	30.67	1.62 %	K V
Lonza Grp	602.20	1.14 %	K V
Swiss Life Hldg	772.20	1.07 %	K V
ABB	51.66	0.86 %	K V
Swiss Re	140.95	0.71 %	K V
Nestle	82.12	-0.44 %	K V
Sika	240.70	-0.58 %	K V
CieFinRichemont	181.80	-0.66 %	K V
Givaudan	4’031.00	-0.69 %	K V
Sonova Hldg	296.10	-2.15 %	K V

mehr

14.02.25		NASDAQ-Handel: NASDAQ Composite letztendlich mit grünem Vorzeichen
14.02.25		Gewinne in New York: So steht der NASDAQ Composite am Freitagnachmittag
14.02.25		Aufschläge in New York: NASDAQ Composite liegt mittags im Plus
13.02.25		NASDAQ-Handel: NASDAQ Composite notiert schlussendlich im Plus
13.02.25		Optimismus in New York: NASDAQ Composite mit Kursplus
13.02.25		Freundlicher Handel in New York: NASDAQ Composite klettert mittags
12.02.25		NASDAQ Composite aktuell: NASDAQ Composite liegt zum Handelsende im Plus
12.02.25		Kaum Veränderungen: NASDAQ Composite am Nachmittag stabil

14.02.25

NASDAQ-Handel: NASDAQ Composite letztendlich mit grünem Vorzeichen

14.02.25

Gewinne in New York: So steht der NASDAQ Composite am Freitagnachmittag

14.02.25

Aufschläge in New York: NASDAQ Composite liegt mittags im Plus

13.02.25

NASDAQ-Handel: NASDAQ Composite notiert schlussendlich im Plus

13.02.25

Optimismus in New York: NASDAQ Composite mit Kursplus

13.02.25

Freundlicher Handel in New York: NASDAQ Composite klettert mittags